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Supplementary Material 
Supplementary Figure Legends 
 
Supplementary Figure 1. Effect of HO-1 depletion on VEGF-induced EC proliferation 
and cytoprotection. HUVEC were transfected with geneFECTOR (GF) alone, control 
siRNA (CTL), or HO-1 siRNAs (seq2, pool) prior to treatment with hemin (0.2 μM) or vehicle 
for 6h. (A) immunoblotting of HO-1 and tubulin with densitometric quantification of HO-1 
relative to hemin-treated positive control EC. (C) HUVEC were transfected with CTLAF488 or 
HO-1 siRNA seq2AF488 prior to immunoblotting for HO-1, HO-2 and tubulin. (C) HUVEC 
were left uninfected or infected with Ad-HO-1 or Ad0 for 24 h prior to immunoblotting of HO-1 
and tubulin. (D and E) HUVEC were left untreated or treated with VEGF (25 ng/ml), ZnPP (5-
20 µM), or VEGF and ZnPP in combination. (D) EC proliferation was quantified by BrdU 
incorporation after 48h, and (E) cell number by MTT assay after 24 h.  Data are presented 
as mean ± SEM (n=3 experiments). *p<0.05, **p<0.01, ***p<0.001 versus UT control. δδ 
p<0.01 and ns = non-significant versus VEGF-treated positive control.  
 
Supplementary Figure 2. HO-1 inhibition impairs microtubule formation. Human 
microvascular EC (HMEC-1) were transfected with CTLAF488 or HO-1 siRNAs (seq2AF488). 
(A) confluent EC monolayers were scratched and migration distance in the absence or 
presence of VEGF (25 ng/ml) for 16h was assessed by live cell imaging. (B) HMEC-1 were 
transfected with control or HO-1 siRNA (seq2, pool) for 24h prior to harvesting and re-
seeding onto Matrigel in the absence or presence of VEGF (25 ng/ml) for 6 h and visualised 
using phase-contrast microscopy. Images from five fields of view were captured and tube 
length quantified using ImageJ (NeuronJ). Data are presented as mean ± SEM (n=3 
experiments), **p<0.01, ***p<0.001. 
 
Supplementary Figure 3. HO-1 inhibition senescence and cyclin regulation. (A) HUVEC 
transfected with CTL or HO-1 siRNAs (seq2 or pool) were left untreated or treated with 
VEGF (25 ng/ml) for 48 h. Senescent cells were identified by SA-β-gal staining. HUVEC 
cultured for 12 passages (P12) acted as a positive control. (B-C) HUVEC were treated with 
geneFECTOR (GF) alone or transfected with CTL or HO-1 siRNAs prior to treatment with 
VEGF (25 ng/ml) or vehicle. (B) cyclin B1 and (C) cyclin D1 mRNAs were quantified by qRT-
PCR. (D-E) Murine EC were treated with GF alone or transfected with CTL, cyclin A1 or HO-
1 siRNAs and after 48 h (D) HO-1 and (E) cyclin A1 mRNAs were quantified by qRT-PCR. 
Data are presented as mean ± SEM (n=3-5 experiments). ns = not significant and δp<0.05 
versus untreated CTL-transfected cells. 
 
Supplementary Figure 4. Difference in gel electrophoresis. A representative DIGE 
fluorescent image showing the overlay of Cy5-labelled Ctrl siRNA + VEGF (red) and Cy3-
labelled HO-1 siRNA + VEGF (green). 
 
Supplementary Figure 5. Vimentin band phosphorylation and αVβ3 expression. (A) 
HUVEC were treated with geneFECTOR (GF) alone or transfected with CTL or HO-1 
siRNAs prior to treatment with VEGF (25 ng/ml) or vehicle for 16h. Protein lysates were 
treated with lambda phosphatase (λ PP, 200 units). Vimentin and GAPDH were analysed by 
by Phos-tagTM SDS-PAGE and immunoblotting. A representative blot from two separate 
experiments is shown. (B) HUVEC were transfected as above prior to treatment with VEGF 
or vehicle for 40 minutes. Integrin αVβ3 expression was analysed by flow-cytometry and 
presented as relative fluorescent intensity, normalized to EC treated with GF alone. Data are 
shown as mean ± SEM (n=4 experiments), ns=not significant.  
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Supplementary Table 1: Cytoskeleton Regulator PCR array results. Changes in mRNA 
expression of siCTL- or siHO-1 siRNA-transfected HUVEC in response to VEGF were assessed 
using a PCR Array. Upregulation of gene expression ≥ 2.00 fold and downregulation ≤ 0.50 fold 
were considered significant changes in gene expression. 
Gene Symbol Gene Name Fold Up- or Down-
Regulation 
ACTR2 ARP2 actin-related protein 2 homolog (yeast) 1.01 
ACTR3 ARP3 actin-related protein 3 homolog(yeast) 0.77 
ARFIP2 ADP-ribosylation factor interacting protein 2 1.34 
ARHGAP6 Rho GTPase activating protein 6 1.16 
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 0.82 
ARHGEF11 Rho guanine nucleotide exchange factor (GEF) 11 1.43 
ARPC1B Actin related protein 2/3 complex, subunit 1B, 41kDa 1.34 
ARPC2 Actin related protein 2/3 complex, subunit 2, 
34kDa 
2.17 
ARPC3 Actin related protein 2/3 complex, subunit 3, 21kDa 0.82 
ARPC4 Actin related protein 2/3 complex, subunit 4, 20kDa 1.54 
ARPC5 Actin related protein 2/3 complex, subunit 5, 16kDa 0.58 
AURKA Aurora kinase A 1.43 
AURKB Aurora kinase B 1.34 
AURKC Aurora kinase C 1.65 
BAIAP2 BAI1-associated protein 2 1.09 
CALD1 Caldesmon 1 0.88 
CALM1 Calmodulin 1 (phosphorylase kinase, delta) 0.95 
CASK Calcium/calmodulin-dependent serine protein kinase 
(MAGUK family) 
1.09 
CCNA1 Cyclin A1 0.44 
CCNB2 Cyclin B2 1.43 
CDC42 Cell division cycle 42 (GTP binding protein, 25kDa) 0.95 
CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) 1.25 
CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 1.01 
CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 1.16 
CDK5 Cyclin-dependent kinase 5 1.43 
CDK5R1 Cyclin-dependent kinase 5, regulatory subunit 1 
(p35) 
1.43 
ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and 
PH domain 1 
1.25 
CFL1 Cofilin 1 (non-muscle) 1.01 
CIT Citron (rho-interacting, serine/threonine kinase 
21) 
2.03 
CLASP1 Cytoplasmic linker associated protein 1 0.88 
CLASP2 Cytoplasmic linker associated protein 2 0.88 
CLIP1 CAP-GLY domain containing linker protein 1 1.09 
CLIP2 CAP-GLY domain containing linker protein 2 1.25 
CRK V-crk sarcoma virus CT10 oncogene homolog (avian) 0.82 
CTTN Cortactin 1.01 
CYFIP1 Cytoplasmic FMR1 interacting protein 1 0.95 
CYFIP2 Cytoplasmic FMR1 interacting protein 2 1.77 
DIAPH1 Diaphanous homolog 1 (Drosophila) 0.95 
DSTN Destrin (actin depolymerizing factor) 1.01 
EZR Ezrin 1.65 
FNBP1L Formin binding protein 1-like 1.16 
FSCN2 Fascin homolog 2, actin-bundling protein, retinal 
(Strongylocentrotus purpuratus) 
2.17 
Supplementary Figure 4 (continued) 
GSN Gelsolin (amyloidosis, Finnish type) 1.09 
IQGAP1 IQ motif containing GTPase activating protein 1 0.88 
IQGAP2 IQ motif containing GTPase activating protein 2 1.09 
LIMK1 LIM domain kinase 1 1.09 
LIMK2 LIM domain kinase 2 0.82 
LLGL1 Lethal giant larvae homolog 1 (Drosophila) 1.25 
MACF1 Microtubule-actin crosslinking factor 1 0.82 
MAP3K11 Mitogen-activated protein kinase kinase kinase 11 1.54 
MAP4 Microtubule-associated protein 4 0.72 
MAPK13 Mitogen-activated protein kinase 13 1.16 
MAPRE1 Microtubule-associated protein, RP/EB family, 
member 1 
0.82 
MAPRE2 Microtubule-associated protein, RP/EB family, 
member 2 
0.58 
MAPT Microtubule-associated protein tau 0.72 
MARK2 MAP/microtubule affinity-regulating kinase 2 1.09 
MID1 Midline 1 (Opitz/BBB syndrome)               0.88 
MSN Moesin 0.62 
MYLK Myosin light chain kinase 1.16 
MYLK2 Myosin light chain kinase 2 1.34 
NCK1 NCK adaptor protein 1 1.01 
NCK2 NCK adaptor protein 2 1.01 
PAK1 P21 protein (Cdc42/Rac)-activated kinase 1 1.43 
PAK4 P21 protein (Cdc42/Rac)-activated kinase 4 1.09 
PFN2 Profilin 2 1.09 
PHLDB2 Pleckstrin homology-like domain, family B, member 2 0.95 
PIKFYVE Phosphoinositide kinase, FYVE finger containing 1.16 
PPP1R12A Protein phosphatase 1, regulatory (inhibitor) subunit 
12A 
1.43 
PPP1R12B Protein phosphatase 1, regulatory (inhibitor) 
subunit 12B 
2.03 
PPP3CA Protein phosphatase 3 (formerly 2B), catalytic 
subunit, alpha isoform 
0.82 
PPP3CB Protein phosphatase 3 (formerly 2B), catalytic 
subunit, beta isoform 
0.51 
RAC1 Ras-related C3 botulinum toxin substrate 1 (rho 
family, small GTP binding protein Rac1) 
0.88 
RACGAP1 Rac GTPase activating protein 1 1.25 
RDX Radixin 0.82 
RHOA Ras homolog gene family, member A 0.82 
ROCK1 Rho-associated, coiled-coil containing protein kinase 1 0.95 
SSH1 Slingshot homolog 1 (Drosophila) 1.16 
SSH2 Slingshot homolog 2 (Drosophila) 0.77 
STMN1 Stathmin 1 1.09 
TIAM1 T-cell lymphoma invasion and metastasis 1 1.65 
VASP Vasodilator-stimulated phosphoprotein 1.01 
WAS Wiskott-Aldrich syndrome (eczema-
thrombocytopenia) 
0.51 
WASF1 WAS protein family, member 1 1.01 
WASL Wiskott-Aldrich syndrome-like 1.16 
 
 
 
Supplementary Table 2. Significantly altered protein spots identified by DIGE LC-MS/MS. 
No
. 
Protein name Accession No. Mw (Da) p value Average 
Ratio* 
# unique 
peptides 
# unique 
spectra 
# total 
spectra 
Sequence 
coverage 
1 Vimentin VIME_HUMAN 53,635 0.013 -2.03 16 18 30 36.30% 
2 Vimentin VIME_HUMAN 53,635 0.016 -1.71 21 25 43 48.30% 
3 Vimentin VIME_HUMAN 53,635 0.0024 -1.69 35 48 90 68.70% 
4 Vimentin VIME_HUMAN 53,635 0.0067 -1.65 38 44 81 79.20% 
5 Vimentin VIME_HUMAN 53,635 0.0068 -1.63 34 40 69 71.00% 
6 Vimentin VIME_HUMAN 53,635 0.0047 -1.66 34 40 76 72.50% 
7 Periodic tryptophan protein 1 homolog PWP1_HUMAN 55,811 0.017 -1.2 3 3 5 6.39% 
8 Lamin-B1 LMNB1_HUMAN 66,392 0.0054 -1.22 4 4 5 7.85% 
8 Ran GTPase-activating protein 1 RAGP1_HUMAN 63,525 0.0054 -1.22 4 4 6 7.84% 
9 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 PLOD2_HUMAN 84,669 0.0046 1.2 8 9 17 13.00% 
10 Nucleolin NUCL_HUMAN 76,598 0.00056 1.21 3 3 6 4.37% 
10 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 PLOD2_HUMAN 84,669 0.00056 1.21 9 9 14 13.70% 
11 Vimentin VIME_HUMAN 53,635 0.0018 -1.91 10 10 16 24.00% 
12 Heterogeneous nuclear ribonucleoprotein K HNRPK_HUMAN 50,961 0.028 -1.24 7 11 19 17.90% 
13 Ras GTPase-activating protein-binding protein 1 G3BP1_HUMAN 52,145 0.02 -1.26 3 3 5 6.22% 
14 Protein disulfide-isomerase A3 PDIA3_HUMAN 56,767 0.026 1.25 11 14 23 23.40% 
15 Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, 
mitochondrial 
SCOT1_HUMAN 56,141 0.01 1.38 5 6 9 10.40% 
16 Pyruvate kinase isozymes M1/M2 KPYM_HUMAN 57,920 0.043 1.23 10 10 19 17.50% 
17 Vimentin VIME_HUMAN 53,635 0.03 -1.52 9 9 15 15.50% 
18 Thioredoxin domain-containing protein 5 TXND5_HUMAN 47,611 0.044 1.36 16 18 31 35.20% 
19 Heterogeneous nuclear ribonucleoprotein F HNRPF_HUMAN 45,654 0.012 1.21 8 11 20 23.40% 
20 Serpin H1 SERPH_HUMAN 46,424 0.012 1.37 17 22 44 40.90% 
21 Eukaryotic translation initiation factor 3 subunit F EIF3F_HUMAN 37,546 0.039 -1.28 6 7 13 21.60% 
21 Perilipin-3 PLIN3_HUMAN 47,028 0.039 -1.28 5 5 9 18.40% 
22 Protein SET SET_HUMAN 33,471 0.037 1.23 7 11 18 22.40% 
23 Tropomyosin alpha-1 chain TPM1_HUMAN 32,692 0.043 -1.29 5 5 7 15.50% 
23 Vimentin VIME_HUMAN 53,635 0.043 -1.29 4 4 7 7.51% 
24 Ubiquitin fusion degradation protein 1 homolog UFD1_HUMAN 34,483 0.047 1.25 3 4 7 7.82% 
25 Heterogeneous nuclear ribonucleoproteins C1/C2 HNRPC_HUMAN 33,653 0.02 1.36 5 5 7 13.40% 
26 Elongation factor 1-delta EF1D_HUMAN 31,104 0.018 -1.24 13 15 25 47.00% 
27 Voltage-dependent anion-selective channel protein 2 VDAC2_HUMAN 31,549 0.018 -1.24 6 6 10 25.50% 
28 Voltage-dependent anion-selective channel protein 2 VDAC2_HUMAN 31,549 0.026 -1.31 2 2 3 6.80% 
29 Elongation factor 1-delta EF1D_HUMAN 31,104 0.027 -1.23 3 3 4 7.12% 
30 Elongation factor 1-beta EF1B_HUMAN 24,746 0.027 -1.23 4 5 7 23.10% 
30 Eukaryotic translation initiation factor 6 IF6_HUMAN 26,580 0.05 -1.2 6 7 13 29.40% 
31 14-3-3 protein epsilon 1433E_HUMAN 29,157 0.018 -1.29 12 16 30 35.30% 
32 Prohibitin PHB_HUMAN 29,787 9.40E-06 -1.24 7 7 13 22.80% 
33 LDLR chaperone MESD MESD_HUMAN 26,060 0.0098 1.41 7 8 16 32.50% 
34 Cysteine and glycine-rich protein 1 CSRP1_HUMAN 20,549 0.038 1.27 9 10 17 50.80% 
35 Transgelin-2 TAGL2_HUMAN 22,374 0.047 -1.43 9 13 23 44.20% 
* Average Ratio is HO-1 siRNA + VEGF / Control siRNA + VEGF. Positive value indicates increased in HO-1 siRNA + VEGF group. Negative value indicates 
decreased in HO-1 siRNA + VEGF group. 
Supplementary Table 2. Proteins differentially expressed between HO-1 deficient and 
control human EC. 29 identified proteins were analysed and grouped according to gene ontology 
(GO) using DAVID Bioinformatics Resources 6.7.  
Cellular Component   
GO Term Count Gene Name  
intracellular organelle lumen 12 SCOT1 
SET 
IF6 
HNRPF 
HNPRK 
LMNB1 
NUCL 
PHB 
PDIA3 
SERPH 
TXNDC5 
VDAC2 
organelle lumen 12 SCOT1 
SET 
IF6 
HNRPF 
HNPRK 
LMNB1 
NUCL 
PHB 
PDIA3 
SERPH 
TXNDC5 
VDAC2 
membrane-enclosed lumen 12 SCOT1 
SET 
IF6 
HNRPF 
HNPRK 
LMNB1 
NUCL 
PHB 
PDIA3 
SERPH 
TXNDC5 
VDAC2 
nuclear lumen 7 SET 
IF6 
HNRPF 
HNPRK 
LMNB1 
NUCL 
PHB 
spliceosome 3 HNRPC 
HNRPF 
HNPRK 
ribonucleoprotein complex 4 HNRPC 
HNRPF 
HNPRK 
NUCL 
nucleoplasm 5 SET 
HNRPF 
HNPRK 
NUCL 
PHB 
nucleolus 4 IF6 
HNRPF 
HNPRK 
NUCL 
organelle envelope 6 RAGP1 
IF6 
LMNB1 
PHB 
TAGL2 
VDAC2 
 
Supplementary Table 2. (cont)   
envelope 6 RAGP1 
IF6 
LMNB1 
PHB 
TAGL2 
VDAC2 
nuclear envelope 4 RAGP1 
IF6 
LMNB1 
TAGL2 
nuclear membrane 3 IF6 
LMNB1 
TAGL2 
organelle inner membrane 3 IF6 
LMNB1 
PHB 
organelle membrane 5 IF6 
LMNB1 
PHB 
TAGL2 
VDAC2 
endomembrane system 4 RAGP1 
IF6 
LMNB1 
TAGL2 
endoplasmic reticulum lumen 3 PDIA3 
SERPH 
TXNDC5 
endoplasmic reticulum 6 SET 
MESD 
PLOD2 
PDIA3 
SERPH 
TXNDC5 
endoplasmic reticulum part 3 SET 
MESD 
PDIA3 
SERPH 
TXNDC5 
integral to membrane 3 RAGP1 
PHB 
VDAC2 
intrinsic to membrane 3 RAGP1 
PHB 
VDAC2 
intermediate filament 3 IF6 
LMNB1 
VIME 
intermediate filament cytoskeleton 3 IF6 
LMNB1 
VIME 
non-membrane-bound organelle 9 RAGP1 
HNRPK 
HNRPF 
IF6 
LMNB1 
NUCL 
TPM1 
VDAC2 
VIME 
intracellular non-membrane bound 
organelle 
9 RAGP1 
HNRPK 
HNRPF 
IF6 
LMNB1 
NUCL 
TPM1 
VDAC2 
VIME 
 
 
Supplementary Table 2. (cont)   
cytoskeletal part 4 IF6 
LMNB1 
TPM1 
VIME 
cytoskeleton 4 IF6 
LMNB1 
TPM1 
VIME 
mitochondrial part 3 SCOT1 
PHB 
VDAC2 
mitochondrion  4 SCOT1 
PHB 
1433E 
VDAC2 
cytosol 9 G3BP1 
SET 
EF1B 
EF1D 
EIF3F 
1433E 
KPYM 
UFD1 
VIME 
plasma membrane 7 G3BP1 
RAGP1 
PLIN3 
PHB 
TAGL2 
TPM1 
VIME 
plasma membrane part  4 RAGP1 
PLIN3 
PHB 
TPM1 
Molecular Function   
GO Term Count  Gene Name 
translation factor activity, nucleic 
acid binding 
  
RNA binding  5 G3BP1 
HNRPC 
HNRPK 
HNRPF 
NUCL 
nucleotide binding 5 G3BP1 
HNRPC 
HNRPF 
NUCL 
VDAC2 
DNA binding 3 G3BP1 
HNRPK 
NUCL 
structural molecule activity 3 LMNB1 
TPM1 
VIME 
metal ion binding 3 CSRP1 
PLOD2 
KPYM 
cation binding 3 CSRP1 
PLOD2 
KPYM 
ion binding  3 CSRP1 
PLOD2 
KPYM 
 
Supplementary Table 2. (cont)   
Biological Process   
GO Term Count Gene Name  
translation 4 EF1B 
EF1D 
EIF3F 
IF6 
RNA splicing, via 
transesterification reactions 
3 HNRPC 
HNRPF 
HNPRK 
nuclear mRNA splicing, via 
spliceosome 
3 HNRPC 
HNRPF 
HNPRK 
RNA splicing 3 HNRPC 
HNRPF 
HNPRK 
mRNA processing 3 HNRPC 
HNRPF 
HNPRK 
mRNA metabolic process 3 HNRPC 
HNRPF 
HNPRK 
RNA processing 3 HNRPC 
HNRPF 
HNPRK 
intracellular transport 5 SET 
PDIA3 
1433E 
TXDN5 
TPM1 
regulation of apoptosis 4 PHB 
PDIA3 
1433E 
TXDN5 
regulation of programmed cell 
death 
4 PHB 
PDIA3 
1433E 
TXDN5 
regulation of cell death 4 PHB 
PDIA3 
1433E 
TXDN5 
cell motion 3 1433E 
TPM1 
VIME 
negative regulation of 
macromolecule metabolic process 
3 SET 
PHB 
1433E 
 
 
 
